Prostaglandin D2 serinol amide (PGD2-SA) is primarily studied for its potential therapeutic applications in the field of ophthalmology. It has shown promise in reducing intraocular pressure, making it a candidate for the treatment of glaucoma. By modulating fluid dynamics within the eye, it helps prevent optic nerve damage and preserves vision. Additionally, PGD2-SA is being investigated for its anti-inflammatory properties, which could be beneficial in managing ocular inflammatory conditions. Its unique mechanism of action offers a novel approach compared to traditional treatments, potentially providing an alternative for patients who do not respond well to conventional therapies. Research is ongoing to further explore its efficacy and safety in clinical settings.